EGIS 8332

Drug Profile

EGIS 8332

Latest Information Update: 15 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egis Pharmaceuticals; Servier
  • Developer Egis Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 15 Dec 2003 No development reported - Preclinical for Neurological disorders (Prevention) in Hungary (unspecified route)
  • 25 Aug 2000 New profile
  • 25 Aug 2000 Preclinical development for Neurological disorders (Prevention) in Hungary (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top